Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
Global Kidney Cancer Drugs Market 2012-2016

Global kidney cancer drugs market: 13% CAGR between 2012-2016


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2014-03-05 15:31:03 - Global Kidney Cancer Drugs Market 2012-2016 - a new market research report on companiesandmarkets.com

The Global Kidney Cancer Drugs market is to grow at a CAGR of 13.4 percent over the period 2012-2016. One of the key factors contributing to this market growth is the growing demand in developing economies. The Global Kidney Cancer Drugs market has also been witnessing an increase in R&D activities. However, over-dependence of the market on the US could pose a challenge to the growth of this market.

The vendors in this market are investing heavily in R&D to develop kidney cancer drugs from biological sources because this approach can increase the efficacy of the drugs. Moreover, vendors are formulating effective injection solutions that can help retain the efficacy of the drug molecule for a longer period. For instance, Pfizer

 

 

Inc. is increasingly focusing on enhancing the efficacy of its kidney cancer drug Sutent. Moreover, vendors are increasing their investment in the R&D of drugs that can be used for the treatment of more than one type of cancer.

The US government has increased expenditure on healthcare because of the prevalence of several diseases, which are largely due to the changing lifestyles of individuals, environmental health hazards, and genetic disorders. As a result, the use of therapeutic drugs for the treatment of cancer has increased. Healthcare spending in the US has increased significantly. Thus, the opportunity for revenue generation has increased, which acts as a driver of the Kidney Cancer Drugs market in the US. Moreover, this increase in healthcare expenditure is expected to increase the quality of treatments as well as the number of R and D projects. This is one of the major drivers contributing to the growth of the Global Kidney Cancer Drugs market.

The key vendors dominating this market space are AVEO Pharmaceuticals Inc., Bayer AG, GlaxoSmithKline plc, Hoffmann-La Roche Ltd., Novartis AG, and Pfizer Inc. The other vendors mentioned in the report are AstraZeneca plc, Onyx Pharmaceuticals Inc., Merck Serono S.A., and WILEX AG.

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com